0001104659-23-100787.txt : 20230914 0001104659-23-100787.hdr.sgml : 20230914 20230914161021 ACCESSION NUMBER: 0001104659-23-100787 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230914 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230914 DATE AS OF CHANGE: 20230914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rezolute, Inc. CENTRAL INDEX KEY: 0001509261 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273440894 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39683 FILM NUMBER: 231255218 BUSINESS ADDRESS: STREET 1: 275 SHORELINE DRIVE, SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-206-4507 MAIL ADDRESS: STREET 1: 275 SHORELINE DRIVE, SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: AntriaBio, Inc. DATE OF NAME CHANGE: 20130114 FORMER COMPANY: FORMER CONFORMED NAME: FITS MY STYLE INC DATE OF NAME CHANGE: 20110104 8-K 1 tm2325841d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 14, 2023

REZOLUTE, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada

001-39683

27-3440894

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

275 Shoreline Drive, Suite 500, Redwood City, CA 94065

(Address of Principal Executive Offices, and Zip Code)

650-206-4507

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	RZLT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On September 14, 2023, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2023. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.		Description
99.1		Press Release, dated September 14, 2023
104		Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REZOLUTE, INC.


DATE: September 14, 2023	By:	/s/Nevan Charles Elam
		Nevan Charles Elam Chief Executive Officer

EX-99.1 2 tm2325841d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023.

“We are delighted that we are poised to initiate sunRIZE -- our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 2024, where we hope to demonstrate the safety and proof-of-concept of our oral therapy for diabetic macular edema,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “As we look ahead to these upcoming milestones, we remain committed to our mission of delivering transformative therapies to patients with devastating metabolic diseases.”

Corporate and Clinical Highlights

·

RZ358, monoclonal antibody for the treatment of congenital hyperinsulinism (HI)

·

Following the successful Phase 2b RIZE study of RZ358 in congenital HI, which demonstrated that RZ358 safely and substantially improved hypoglycemia, the Company plans to initiate sunRIZE, a pivotal Phase 3 clinical study of RZ358, in Europe and other geographies outside the US in Q4 2023. Topline results from the sunRIZE study are expected in the first half of 2025.

·

RZ402, oral plasma kallikrein inhibitor to treat diabetic macular edema (DME)

·

In December 2022, Rezolute announced the initiation of a Phase 2 study of RZ402 in patients with DME. This is a multi-center, randomized, double-masked, placebocontrolled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naïve to or have received limited anti-VEGF injections. Study enrollment is ongoing, and the Company anticipates topline results from this study in the first quarter of 2024.

Fourth Quarter and Full Year Fiscal 2023 Financial Results

·

Cash and cash equivalents totaled $16.0 million and investments in marketable debt securities totaled $102.3 million as of June 30, 2023.

·

Research and development (R&D) expenses were $10.9 million for the fourth quarter of fiscal 2023, compared to $8.6 million for the same period in fiscal 2022. Full fiscal year 2023 R&D expenses were $43.8 million, compared to $32.5 million in fiscal year 2022. The increase from fiscal year 2022 to fiscal year 2023 was primarily due to increased expenditures in clinical trial activities, manufacturing costs and higher personnel-related expenses, which included employee compensation and stock-based compensation.

·

General and administrative (G&A) expenses were $3.3 million for the fourth quarter of fiscal 2023, compared to $2.7 million for the same period in fiscal 2022. Full fiscal year 2023 G&A expenses were $12.2 million, compared to $9.4 million in fiscal year 2022. The increase from fiscal year 2022 to fiscal year 2023 was primarily due to higher personnel-related expenses, including employee compensation and stock-based compensation.

·

Net loss was $12.7 million for the fourth quarter of fiscal 2023, compared to $9.4 million for the same period in fiscal 2022. Full year fiscal 2023 net loss was $51.8 million compared to net loss of $41.1 million for the fiscal year 2022.

About Rezolute, Inc.

Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician, and advocate voices are integrated in the Company’s drug development process, enabling Rezolute to boldly address a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients’ lives. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter or LinkedIn.

Forward-Looking Statements

The information provided herein contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. The “forward-looking statements” include, but are not limited to, statements regarding receiving results from the Phase 2 study of RZ402 in the first quarter of 2024, the ability of RZ358 to treat congenital hyperinsulinism, the timing of the release topline results from sunRIZE, and our ability to meet trial enrollment goals.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Rezolute’s current beliefs, expectations and assumptions regarding the future of its businesses, results of and timing of clinical trials, financial condition and results of operations, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Rezolute’s control. Rezolute’s actual results including the timing and results of clinical trials may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause Rezolute’s actual results including the timing and results of clinical trials to differ materially from those indicated in the forward-looking statements are discussed or identified in Rezolute’s filings made with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Rezolute in this information are based only on information currently available to Rezolute and speak only as of the date on which the statement is made. Rezolute undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise except as required by applicable law.

Investor:

Kimberly Minarovich

Argot Partners

rezolute@argotpartners.com

212-600-1902

Media:

media-relations@rezolutebio.com

Rezolute, Inc.

Condensed Consolidated Financial Statements Data

(in thousands, except per share data)

		Three Months Ended								Year Ended
		June 30,								June 30,
		2023				2022				2023				2022
Condensed Consolidated Statements of Operations Data:

Operating expenses:
Research and development		$	10,933			$	8,574			$	43,813			$	32,486
General and administrative			3,305				2,725				12,177				9,357
Total operating expenses			14,238				11,299				55,990				41,843
Loss from operations			(14,238	)			(11,299	)			(55,990	)			(41,843	)
Non-operating income (expense), net			1,510				1,876				4,203				783
Net loss		$	(12,728	)		$	(9,423	)		$	(51,787	)		$	(41,060	)

Net loss per common share
Basic		$	(0.25	)		$	(0.30	)		$	(1.01	)		$	(2.26	)
Diluted		$	(0.25	)		$	(0.37	)		$	(1.01	)		$	(2.32	)

Weighted average number of common shares outstanding:
Basic			51,410				31,429				51,188				18,197
Diluted			51,410				36,302				51,188				19,487

		June 30,				June 30,
		2023				2022
Condensed Consolidated Balance Sheets Data:
Cash and cash equivalents		$	16,036			$	150,410
Investments in marketable debt securities			102,330				-
Working capital			99,710				149,642
Total assets			123,721				152,420
Accumulated deficit			(260,984	)			(209,198	)
Total stockholders’ equity			123,721				149,471

EX-101.SCH 3 rzlt-20230914.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rzlt-20230914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 rzlt-20230914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2325841d1_ex99-1img001.jpg GRAPHIC begin 644 tm2325841d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 14, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 14, 2023
Entity File Number	001-39683
Entity Registrant Name	REZOLUTE, INC.
Entity Central Index Key	0001509261
Entity Tax Identification Number	27-3440894
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	275 Shoreline Drive
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	650
Local Phone Number	206-4507
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	RZLT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 tm2325841d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001509261 2023-09-14 2023-09-14 iso4217:USD shares iso4217:USD shares 0001509261 false 8-K 2023-09-14 REZOLUTE, INC. NV 001-39683 27-3440894 275 Shoreline Drive Suite 500 Redwood City CA 94065 650 206-4507 false false false false Common Stock, par value $0.001 per share RZLT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rezolutebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2325841d1_8k.htm rzlt-20230914.xsd rzlt-20230914_lab.xml rzlt-20230914_pre.xml tm2325841d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2325841d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2325841d1_8k.htm" ] }, "labelLink": { "local": [ "rzlt-20230914_lab.xml" ] }, "presentationLink": { "local": [ "rzlt-20230914_pre.xml" ] }, "schema": { "local": [ "rzlt-20230914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rzlt", "nsuri": "http://rezolutebio.com/20230914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325841d1_8k.htm", "contextRef": "AsOf2023-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://rezolutebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325841d1_8k.htm", "contextRef": "AsOf2023-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://rezolutebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-100787-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-100787-xbrl.zip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end